While KYNA has been found to be an endogenous activator of GPR35 in humans and rats altering immune responses in inflammation, pain, cancer, cardiovascular disease and energy homeostasis [Reviewed In: [111]], its role as an activator of GPR35 in other species remains unknown. The gene discussed is GPR35; the disease is cardiovascular disorder.